all-trans-retinol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases bronchopulmonary dysplasia of any grade at 36 weeks
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“The meta-analysis supported a reduction in the risk of BPD at the postmenstrual age of 36 weeks in the vitamin A treatment group (RR, 0.88; 95% CI, 0.77–0.99; moderate quality of evidence).”
Quoted verbatim from Vitamin A to prevent bronchopulmonary dysplasia in extremely low birth weight infants: a systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Extremely low birth weight infants (birth weight under 1,000 g) in four randomised trials; vitamin A given intramuscularly in three trials and orally in one, versus sham injection or placebo liquid; oxygen-dependent survivors at 36 weeks postmenstrual age
Effect 0.88 risk ratio, 95% CI 0.77 to 0.99
Vitamin A to prevent bronchopulmonary dysplasia in extremely low birth weight infants: a systematic review and meta-analysis.2018PMID:30496228Permalink
Keep reading
- Everything the graph holds on all-trans-retinol
- Every compound studied against Bronchopulmonary dysplasia of any grade at 36 weeks
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M5JQFST19YK3ASHDMBZ1BRB5